Patents by Inventor Zachary C. Hartman
Zachary C. Hartman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12083172Abstract: Methods of reducing the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding a HER2 polypeptide or a truncation, deletion or substitution mutant thereof. Methods of using the vaccine including the polynucleotide encoding the HER2 polypeptide to treat a cancer or precancer are also provided. The vaccines may be administered with a cancer therapeutic or prevention agent or a checkpoint inhibitor immunomodulatory agent.Type: GrantFiled: November 19, 2020Date of Patent: September 10, 2024Assignee: Duke UniversityInventors: Herbert K. Lyerly, Takuya Osada, Zachary C. Hartman
-
Patent number: 11253580Abstract: Disclosed are compositions, methods, and kits for treating a cancer or pre-cancer. In particular, the invention generally relates to cancer vaccines as well as methods of delivering the vaccines. Combination treatments including the vaccines in combination with immunomodulatory agents are also contemplated.Type: GrantFiled: January 9, 2017Date of Patent: February 22, 2022Assignee: DUKE UNIVERSITYInventors: Herbert K. Lyerly, Takuya Osada, Zachary C. Hartman
-
Patent number: 11235043Abstract: Methods of reducing, the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering the cancer therapeutic or prevention agent and a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding a HER3 polypeptide. Methods of using the vaccine including the polynucleotide encoding the HER3 polypeptide to treat a cancer or precancer are also provided.Type: GrantFiled: April 25, 2018Date of Patent: February 1, 2022Assignee: Duke UniversityInventors: Herbert K. Lyerly, Michael A. Morse, Takuya Osada, Timothy M. Clay, Zachary C. Hartman
-
Patent number: 11224665Abstract: The invention generally relates to compositions and methods for preventing and treating cancer. More specifically, the invention relates to MAVS compositions and their use in cancer therapeutics that may be used to treat various cancers alone or in combination with other anti-cancer therapeutic agents.Type: GrantFiled: October 5, 2017Date of Patent: January 18, 2022Assignee: Duke UniversityInventors: Herbert K. Lyerly, Zachary C. Hartman
-
Publication number: 20210330773Abstract: Methods of reducing the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering the cancer therapeutic or prevention agent, such as a checkpoint inhibitor and a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding a HER3 polypeptide. Methods of using the vaccine including the polynucleotide encoding the HER3 polypeptide to treat a cancer or precancer are also provided.Type: ApplicationFiled: May 24, 2021Publication date: October 28, 2021Applicant: Duke UniversityInventors: Herbert K. Lyerly, Michael A. Morse, Takuya Osada, Timothy M. Clay, Zachary C. Hartman
-
Publication number: 20210077606Abstract: Methods of reducing the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding a HER2 polypeptide or a truncation, deletion or substitution mutant thereof. Methods of using the vaccine including the polynucleotide encoding the HER2 polypeptide to treat a cancer or precancer are also provided. The vaccines may be administered with a cancer therapeutic or prevention agent or a checkpoint inhibitor immunomodulatory agent.Type: ApplicationFiled: November 19, 2020Publication date: March 18, 2021Applicant: Duke UniversityInventors: Herbert K. Lyerly, Takuya Osada, Zachary C. Hartman
-
Publication number: 20210069309Abstract: Methods of reducing the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering the cancer therapeutic or prevention agent and a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding an ESR1 polypeptide or a truncation, deletion or substitution mutant thereof. Methods of using the vaccine including the polynucleotide encoding the ESR1 polypeptide to treat a cancer or precancer are also provided.Type: ApplicationFiled: November 19, 2020Publication date: March 11, 2021Applicant: Duke UniversityInventors: Herbert K. Lyerly, Takuya Osada, Zachary C. Hartman
-
Patent number: 10842857Abstract: Methods of reducing the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding a HER2 polypeptide or a truncation, deletion or substitution mutant thereof. Methods of using the vaccine including the polynucleotide encoding the HER2 polypeptide to treat a cancer or precancer are also provided. The vaccines may be administered with a cancer therapeutic or prevention agent or a checkpoint inhibitor immunomodulatory agent.Type: GrantFiled: July 25, 2018Date of Patent: November 24, 2020Assignee: DUKE UNIVERSITYInventors: Herbert K. Lyerly, Takuya Osada, Zachary C. Hartman
-
Patent number: 10842855Abstract: Methods of reducing the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering the cancer therapeutic or prevention agent and a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding an ESR1 polypeptide or a truncation, deletion or substitution mutant thereof. Methods of using the vaccine including the polynucleotide encoding the ESR1 polypeptide to treat a cancer or precancer are also provided.Type: GrantFiled: July 24, 2018Date of Patent: November 24, 2020Assignee: DUKE UNIVERSITYInventors: Herbert K. Lyerly, Takuya Osada, Zachary C. Hartman
-
Patent number: 10487143Abstract: The invention generally relates to compositions and methods for preventing and treating cancer. More specifically, the invention relates to antigenic polypeptides and their use in cancer vaccines that may be used, in part, to treat cancer types dependent upon HER2-mediated signaling.Type: GrantFiled: October 5, 2017Date of Patent: November 26, 2019Assignee: Duke UniversityInventors: Herbert K. Lyerly, Takuya Osada, Zachary C. Hartman
-
Publication number: 20190022204Abstract: Disclosed are compositions, methods, and kits for treating a cancer or pre-cancer. In particular, the invention generally relates to cancer vaccines as well as methods of delivering the vaccines. Combination treatments including the vaccines in combination with immunomodulatory agents are also contemplated.Type: ApplicationFiled: January 9, 2017Publication date: January 24, 2019Applicant: DUKE UNIVERSITYInventors: Herbert K. Lyerly, Takuya Osada, Zachary C. Hartman
-
Publication number: 20180344824Abstract: Methods of reducing the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding a HER2 polypeptide or a truncation, deletion or substitution mutant thereof. Methods of using the vaccine including the polynucleotide encoding the HER2 polypeptide to treat a cancer or precancer are also provided. The vaccines may be administered with a cancer therapeutic or prevention agent or a checkpoint inhibitor immunomodulatory agent.Type: ApplicationFiled: July 25, 2018Publication date: December 6, 2018Applicant: Duke UniversityInventors: Herbert K. Lyerly, Takuya Osada, Zachary C. Hartman
-
Publication number: 20180326030Abstract: Methods of reducing the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering the cancer therapeutic or prevention agent and a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding an ESR1 polypeptide or a truncation, deletion or substitution mutant thereof. Methods of using the vaccine including the polynucleotide encoding the ESR1 polypeptide to treat a cancer or precancer are also provided.Type: ApplicationFiled: July 24, 2018Publication date: November 15, 2018Applicant: Duke UniversityInventors: Herbert K. Lyerly, Takuya Osada, Zachary C. Hartman
-
Publication number: 20180311329Abstract: Methods of reducing the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering the cancer therapeutic or prevention agent and a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding a HER3 polyepptide. Methods of using the vaccine including the polynucleotide encoding the HER3 polypeptide to treat a cancer or precancer are also provided.Type: ApplicationFiled: April 25, 2018Publication date: November 1, 2018Applicant: Duke UniversityInventors: Herbert K. Lyerly, Michael A. Morse, Takuya Osada, Timothy M. Clay, Zachary C. Hartman
-
Publication number: 20180282736Abstract: The present inventors provide HER3 vaccine vector compositions and methods of using the same. More specifically, the present inventors demonstrate, in part, that a combination of HER3 vaccine vectors with checkpoint inhibitors suppresses or eliminates cancer cells more effectively than either alone.Type: ApplicationFiled: April 2, 2018Publication date: October 4, 2018Applicant: Duke UniversityInventors: Herbert K. Lyerly, Takuya Osada, Zachary C. Hartman
-
Patent number: 9956276Abstract: Methods of reducing the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering the cancer therapeutic or prevention agent and a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding a HER3 polypeptide. Methods of using the vaccine including the polynucleotide encoding the HER3 polypeptide to treat a cancer or precancer are also provided.Type: GrantFiled: January 21, 2013Date of Patent: May 1, 2018Assignee: Duke UniversityInventors: Herbert K. Lyerly, Michael A. Morse, Takuya Osada, Timothy M. Clay, Zachary C. Hartman
-
Publication number: 20180094050Abstract: The invention generally relates to compositions and methods for preventing and treating cancer. More specifically, the invention relates to antigenic polypeptides and their use in cancer vaccines that may be used, in part, to treat cancer types dependent upon HER2-mediated signaling.Type: ApplicationFiled: October 5, 2017Publication date: April 5, 2018Applicant: Duke UniversityInventors: Herbert K. Lyerly, Takuya Osada, Zachary C. Hartman
-
Publication number: 20180092989Abstract: The invention generally relates to compositions and methods for preventing and treating cancer. More specifically, the invention relates to MAVS compositions and their use in cancer therapeutics that may be used to treat various cancers alone or in combination with other anti-cancer therapeutic agents.Type: ApplicationFiled: October 5, 2017Publication date: April 5, 2018Applicant: Duke UniversityInventors: Herbert K. Lyerly, Zachary C. Hartman
-
Publication number: 20170196952Abstract: Methods of reducing the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering the cancer therapeutic or prevention agent and a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding an ESR1 polypeptide or a truncation, deletion or substitution mutant thereof. Methods of using the vaccine including the polynucleotide encoding the ESR1 polypeptide to treat a cancer or precancer are also provided.Type: ApplicationFiled: July 7, 2015Publication date: July 13, 2017Applicant: Duke UniversityInventors: Herbert K. Lyerly, Takuya Osada, Zachary C. Hartman
-
Publication number: 20170196953Abstract: Methods of reducing the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding a HER2 polypeptide or a truncation, deletion or substitution mutant thereof. Methods of using the vaccine including the polynucleotide encoding the HER2 polypeptide to treat a cancer or precancer are also provided. The vaccines may be administered with a cancer therapeutic or prevention agent or a checkpoint inhibitor immunomodulatory agent.Type: ApplicationFiled: July 7, 2015Publication date: July 13, 2017Applicant: Duke UniversityInventors: Herbert K. Lyerly, Takuya Osada, Zachary C. Hartman